Popular diabetes and weight-loss drugs known as GLP-1s are helping to boost the biopharma sector's return on investment this ...
Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company that specializes in diabetes care and other chronic ...
Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different ...
10h
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
Novo Nordisk and United Laboratories International’s subsidiary, United Biotechnology Co. have entered into a potentially $2 ...
California Made A Big Bet On Producing Its Own Insulin. There’s No ‘Date Certain’ For Delivery
This story was originally published by CalMatters. Sign up for their newsletters. By Kristen Hwang, CalMatters Two years ago, ...
The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.
Investor's Business Daily on MSN12h
Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's weight-loss drug for $200 million up ...
On the Frankfurt Stock Exchange, SAP gained 1,2% to 254.975 and reached a capitalization of almost 313 billion, higher than ...
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...
Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback